

Table SI. Comparison of baseline characteristics in the no-TRC and TRC groups.

Characteristics	No TRC (n=14)	TRC (n=22)	P-value
Median age (range), years	59 (29-76)	63 (29-85)	0.797
Sex, n (%)			
Male	9 (64.3)	11 (50.0)	0.501
Female	5 (35.7)	11 (50.0)	
BMI ^a	24.27±1.198	23.49±0.866	0.593
Comorbidity, n (%)			
Heart disease	0 (0.0)	0 (0.0)	>0.999
Hypertension	5 (29.4)	3 (15.8)	0.217
Diabetes	2 (14.3)	3 (13.6)	>0.999
Hypercholesterolemia	4 (28.6)	6 (27.3)	>0.999
Hypertriglyceridemia	3 (21.4)	8 (36.4)	0.467
Clinical stage, n (%)			
I-II	5 (35.7)	5 (22.7)	0.462
III-IV	9 (64.3)	17 (77.3)	
B-symptoms, n (%)	35.7	22.7	0.462

^aMean ± standard error. Independent samples t-test was used in the analysis of BMI. Mann-Whitney U tests were used in the analyses of SRS, SMS rest and STS rest. Sex, clinical stage and B-symptoms were evaluated with the χ^2 test or Fisher's exact test. BMI, body mass index; TRC, treatment-related cardiotoxicity.

Table SII. Comparison of plasma markers in no-TRC and TRC groups after chemotherapy.

Plasma markers	No TRC (n=14)	TRC (n=22)	P-value
FBS, mmol/l	5.350 (1.165)	5.285 (1.550)	0.606
TC, mmol/l	4.67±0.234	4.755±0.197	0.786
HDL, mmol/l	1.077±0.078	1.198±0.065	0.248
LDL, mmol/l	2.854±0.183	2.896±0.176	0.879
TG, mmol/l	1.505 (0.645)	1.38 (1.802)	0.770
ALT, U/l	17 (15.50)	19.5 (15.75)	0.427
Creatinine, mmol/l	62.675±5.967	71.8±3.110	0.148
D-Dimer, mg/l	0.41 (4.055)	0.39 (0.225)	0.733
WBC ($\times 10^9/l$)	3.815 (2.218)	5.056 (2.190)	0.055
Hemoglobin, g/l	127.714±3.931	130.600±3.975	0.621
Platelets ($\times 10^9/l$)	166.286±14.446	201.750±14.891	0.109
RDW, %	13.979±0.399	13.580±0.304	0.425
β 2-MG, mg/l	1.982±0.197	2.123±0.188	0.608
CRP, mg/l	3.815 (2.218)	5.075 (2.21)	0.173
PCT, ng/ml	0.083±0.0186	0.120±0.050	0.469
BNP, pg/ml	20 (38)	30 (42)	0.058
AST, U/l	27 (11.25)	26 (9)	0.548
LDH, U/l	529.667±28.374	551.514±31.089	0.642
CK, U/l	55.5 (38)	51 (40.5)	0.940
CK-MB, ng/ml	1 (1.3)	0.9 (1.0)	0.599
Troponin, μ g/l	0.002 (0.003)	0.003 (0.003)	0.330
Myoglobin, ng/ml	16.65 (8.075)	16.6 (13.600)	0.822

Data are presented as mean \pm standard error or median (interquartile range). Independent samples t-tests were used in the analyses of TC, HDL, LDL, creatinine, hemoglobin, platelets, RDW, β 2-MG, PCT and LDH. Mann-Whitney tests were used in the analyses of FBS, TG, ALT, D-Dimer, WBC, CRP, BNP, AST, CK, CK-MB, troponin and myoglobin. FBS, fasting blood sugar; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triacylglycerol; ALT, alanine aminotransferase; BUN, blood urea nitrogen; WBC, white blood cell; RDW, red blood cell distribution width; β 2-MG, β 2-microglobulin; CRP, C-reactive protein; PCT, procalcitonin; BNP, brain natriuretic peptide; AST, aspartate transaminase; LDH, lactic dehydrogenase; CK, creatine kinase.

Table SIII. Comparison of markers in echocardiography and electrocardiogram in the no-TCR and TCR groups after chemotherapy.

	No TRC (n=14)	TRC (n=22)	P-value
Echocardiography			
LAD, mm	36.0 (5.0)	33.5 (5.5)	0.070
LVEDD, mm	47.000±1.388	46.778±1.382	0.916
LVESD, mm	31.0 (4.00)	30.5 (6.25)	0.541
IVST, mm	9 (1.00)	9 (1.25)	0.160
LVPWT, mm	9 (1.00)	9 (1.25)	0.115
LVEF, %	62 (4.00)	63 (3.25)	0.820
Electrocardiogram			
Heart rate, bpm	82±4.414	79±1.593	0.498
PR interval, msec	152.5 (29.75)	157.5 (31.75)	0.436
QRS interval, msec	98 (10.5)	101 (13.5)	0.294
QT interval, msec	357 (33.75)	375 (36.50)	0.432
QTc interval, msec	429.083±4.728	429.500±4.637	0.953

Data are presented as mean ± standard error or median (interquartile range). Independent samples t-tests were used in the analyses of LVEDD, heart rate and QTc interval. Mann-Whitney U tests were used in the analyses of LAD, LVESD, IVST, LVPWT, LVEF, PR interval, QRS interval and QT interval. LAD, left atrial diameter; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; QTc, corrected QT.